WallStSmart

Aveanna Healthcare Holdings Inc (AVAH)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 2314% more annual revenue ($58.74B vs $2.43B). AZN leads profitability with a 17.4% profit margin vs 9.3%. AVAH trades at a lower P/E of 6.2x. AZN earns a higher WallStSmart Score of 64/100 (C+).

AVAH

Buy

62

out of 100

Grade: C+

Growth: 8.7Profit: 7.5Value: 8.3Quality: 5.0

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVAHUndervalued (+57.0%)

Margin of Safety

+57.0%

Fair Value

$18.54

Current Price

$6.61

$11.93 discount

UndervaluedFair: $18.54Overvalued
AZNUndervalued (+4.1%)

Margin of Safety

+4.1%

Fair Value

$214.51

Current Price

$187.37

$27.14 discount

UndervaluedFair: $214.51Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVAH4 strengths · Avg: 9.5/10
P/E RatioValuation
6.2x10/10

Attractively priced relative to earnings

Return on EquityProfitability
61.6%10/10

Every $100 of equity generates 62 in profit

EPS GrowthGrowth
465.2%10/10

Earnings expanding 465.2% YoY

Revenue GrowthGrowth
27.4%8/10

Revenue surging 27.4% year-over-year

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$287.11B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

Areas to Watch

AVAH1 concerns · Avg: 3.0/10
Market CapQuality
$1.42B3/10

Smaller company, higher risk/reward

AZN4 concerns · Avg: 3.5/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AVAH

The strongest argument for AVAH centers on P/E Ratio, Return on Equity, EPS Growth. Revenue growth of 27.4% demonstrates continued momentum.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bear Case : AVAH

The primary concerns for AVAH are Market Cap.

Bear Case : AZN

The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.

Key Dynamics to Monitor

AVAH profiles as a growth stock while AZN is a value play — different risk/reward profiles.

AVAH carries more volatility with a beta of 2.09 — expect wider price swings.

AVAH is growing revenue faster at 27.4% — sustainability is the question.

AZN generates stronger free cash flow (1.4B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (64/100 vs 62/100), backed by strong 17.4% margins. AVAH offers better value entry with a 57.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aveanna Healthcare Holdings Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Aveanna Healthcare Holdings Inc., a diversified home care platform company, offers private duty nursing (PDN) services, adult home health and palliative care, pediatric home therapy, and enteral nutrition services in the United States. The company is headquartered in Atlanta, Georgia.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?